All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What novel targeted therapies are currently under investigation for R/R CLL?

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, What novel targeted therapies are currently under investigation for relapsed/refractory chronic lymphocytic leukemia (R/R CLL)?

What novel targeted therapies are currently under investigation for R/R CLL?

Tam summarizes key data on novel agents presented at ASCO, including TG-1701, an irreversible BTK inhibitor, and APG-2575, a selective BCL-2 inhibitor. He then presents the ELEVATE phase III trial, which compared acalabrutinib with ibrutinib in patients with R/R CLL.

Share: